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Glycogen synthase kinase 3 comprises two
isoforms (GSK-3a and GSK-3b) that are impli-
cated in type II diabetes, neurodegeneration,
and cancer. GSK-3 activity is elevated in human
and rodent models of diabetes, and various
GSK-3 inhibitors improve glucose tolerance
and insulin sensitivity in rodent models of obe-
sity and diabetes. Here, we report the genera-
tion of mice lacking GSK-3a. Unlike GSK-3b
mutants, which die before birth, GSK-3a knock-
out (GSK-3a KO) animals are viable but dis-
play enhanced glucose and insulin sensitivity
accompanied by reduced fat mass. Fasted
and glucose-stimulated hepatic glycogen
content was enhanced in GSK-3a KO mice,
whereas muscle glycogen was unaltered. Insu-
lin-stimulated protein kinase B (PKB/Akt) and
GSK-3b phosphorylation was higher in GSK-
3a KO livers compared to wild-type littermates,
and IRS-1 expression was markedly increased.
We conclude that GSK-3 isoforms exhibit
tissue-specific physiological functions and
that GSK-3a KOmice are insulin sensitive, rein-
forcing the potential of GSK-3 as a therapeutic
target for type II diabetes.
INTRODUCTION
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine
kinase first identified as one of the primary regulators of
glycogen synthase (GS) (Embi et al., 1980). GSK-3 exists
as two ubiquitously expressed homologs, GSK-3a
(51 kDa) and GSK-3b (46 kDa), which share 98% se-
quence similarity in their catalytic domains but differ in
their N- and C-terminal regions (Woodgett, 1990). GSK-3
is constitutively active in unstimulated cells and is inacti-
vated by a variety of cellular stimuli. The best documented
signaling pathway resulting in GSK-3 inactivation is trig-
gered by insulin, which initiates a cascade of events that
activate protein kinase B/Akt (PKB/Akt), which in turnCell Mphosphorylates a key serine residue located near the N
terminus of GSK-3 (Ser21 of GSK-3a and Ser9 of
GSK-3b), resulting in inactivation of GSK-3 (Frame et al.,
2001). GSK-3 phosphorylates four of nine GS regulatory
serine residues (Ser641, Ser645, Ser649, and Ser653),
which play a critical role in inhibiting GS activity and hence
glycogen synthesis (Roach, 2002).
Insulin resistance is key in the pathogenesis of obesity
and type II diabetes and is characterized by the failure of
insulin-sensitive tissues to efficiently absorb and store
glucose in response to insulin (Kaidanovich and Eldar-
Finkelman, 2002). Since GSK-3 is normally active, its inac-
tivation by insulin is considered essential for a normal
insulin catabolic response. Numerous studies have impli-
cated dysregulation of GSK-3 in the pathogenesis of insu-
lin resistance and type II diabetes. Elevated GSK-3 activity
and expression have been observed in obese and diabetic
humans and rodents (Eldar-Finkelman et al., 1999; Nikou-
lina et al., 2000) and in the adipose tissue of high-fat-fed
mice (Eldar-Finkelman et al., 1999). Recent studies have
also demonstrated that inhibition of GSK-3 using small-
molecule or peptide inhibitors improves insulin action
and glucose homeostasis in rodent models (Dokken
et al., 2005; Kaidanovich-Beilin and Eldar-Finkelman,
2006).
The majority of prior research has focused on the b
isoform of GSK-3, while relatively little is known about
GSK-3a. Here, we have generated GSK-3a knockout
(GSK-3a KO) mice, characterization of which shows that
each isoform displays unique tissue-specific physiological
functions. Loss of GSK-3a results in not only improved
glucose tolerance in response to a glucose load but
also, strikingly, elevated hepatic glycogen storage and
insulin sensitivity.
RESULTS
Generation of GSK-3a KO Mice
Conditional GSK-3a KO mice were generated by intro-
ducing LoxP sites flanking exon 2 of the GSK-3a gene
through homologous recombination (Figure 1A; described
previously in Doble et al. [2007]). Germline deletion of
GSK-3a exon 2was accomplished by crossing the hetero-
zygous conditional KO mice with a pCAGGS (chicken b-
actin) Cre deleter mouse strain. Mating of Cre-deletedetabolism 6, 329–337, October 2007 ª2007 Elsevier Inc. 329
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Tissue-Specific Roles of GSK-3aFigure 1. Targeting Strategy, Protein Expression, and Hormone/Triglyceride Levels of GSK-3a KO Mice
(A) Proper homologous recombination between the GSK-3a locus and the targeting vector results in the replacement of exon 2 (E2) with a LoxP-
flanked exon 2 and a neomycin resistance cassette (Neo) flanked by FRT recombination sites. A = ApaI sites; triangles = LoxP sites; ovals = FRT sites,
DTApA = diphtheria toxin negative selection cassette; asterisks = Southern blot probe hybridization sites; bolded line segments = ‘‘arms’’ of
homology.
(B) Southern blot analysis of five independent G418-resistant ES cell clones. Genomic DNA was digested with ApaI and analyzed with the probes
indicated in (A). Four of the five clones analyzed had expected band patterns.
(C) The indicated tissue lysate (20 mg protein) was resolved by SDS-PAGE and immunoblotted with antibodies against GSK-3a/b. Loading was mon-
itored using antibodies to GAPDH. Blots are representative of three separate experiments.
(D) Heart, liver, muscle, and testes from 8-week-old GSK-3aKO animals (/) andWT littermate controls (+/+) were extracted and lysed as described
in Experimental Procedures, and proteins were resolved by SDS-PAGE. Proteins were detected by immunoblottingwith antibodies against b-catenin.
(E) Adiponectin, leptin, and triglyceride concentrations were determined in 8-week-old male GSK-3a KO animals and WT littermate controls under
fasted and fed conditions. Values are mean ± SEM from at least five separate animals.GSK-3a heterozygous animals generated GSK-3a KO,
heterozygous, and wild-type (WT) littermate control
mice. GSK-3a KO mice were both viable and fertile and
displayed body mass similar to WT littermates (see Fig-
ure S1A in the Supplemental Data available with this
article online).
Antibodies specific for GSK-3a and b were used to
demonstrate loss of GSK-3a expression in all tissues
tested (Figure 1C). Analysis of b-catenin protein levels
demonstrated that inactivation of GSK-3a does not result
in b-catenin stabilization (Figure 1D). Analysis of plasma
adiponectin and triglyceride concentrations revealed no
significant differences between GSK-3a KO and WT ani-
mals under fasted or fed conditions (Figure 1E). Plasma
leptin concentrations were found to be slightly, although
not significantly, lower in GSK-3aKOanimals under fasted330 Cell Metabolism 6, 329–337, October 2007 ª2007 Elsevierconditions. However, fed leptin levels were significantly
lower in KO mice compared to WT control animals. Abso-
lute food consumption over a 24 hr period was compara-
ble between the two animal groups (Figure S1B).
GSK-3a KO Mice Exhibit Improved
Glucose Clearance
To test whether global loss of GSK-3a resulted in improved
glucose and insulin sensitivity, we performed glucose and
insulin tolerance tests. GSK-3a KO mice exhibited signifi-
cant glycemic excursion after intraperitoneal (i.p.) glucose
administration (Figure 2A). The improvedglucose tolerance
could be attributed to enhanced insulin secretion and/or
improved insulin sensitivity. Fasted and fed plasma insulin
concentrations were found to be similar in WT and GSK-
3a KO mice (0.12 ± 0.01 ng/ml versus 0.11 ± 0.01 ng/mlInc.
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Tissue-Specific Roles of GSK-3aFigure 2. Glucose Tolerance, Insulin Sensitivity, Plasma Insulin Concentration, and Body Mass in GSK-3a KO and WT Mice
(A) Blood glucose concentration in 8-week-old male GSK-3a KO animals () and WT littermates (B) was measured at the indicated times following
administration of 2mg/g glucose by i.p. injection. Inset depicts the area under the curve (AUC) forWT (white bars) and KO (black bars) animals. nR 12
animals; *p < 0.001 versus WT. In this and all other figures, error bars represent the standard error of the mean.
(B) Plasma insulin concentration was determined in 8-week-old male GSK-3a KO animals (black bars) and WT littermates (white bars) under fasted
and fed conditions and 15, 30, and 120 min following an i.p. injection of glucose. n = 8 animals; *p < 0.05 versus the respective fasted control.
(C) Insulin tolerancewas determined bymeasuring blood glucose concentration in 8-week-oldmale GSK-3aKOanimals () andWT littermates (B) at
the indicated times following i.p. injection of 1mU/g insulin as described in Experimental Procedures. nR 12 animals; *p < 0.001 versusWT for 15min;
*p < 0.01 versus WT for 30 min and 45 min.
(D) Total body fat and lean mass normalized to body weight in GSK-3a KO (black bars) and WT littermate control (white bars) mice. n = 6 animals;
*p < 0.05 versus WT.in the fasted state, respectively; 1.03 ± 0.15 ng/ml versus
0.79 ± 0.09 ng/ml in the fed state, respectively;
Figure2B). Furthermore,glucose-stimulatedplasma insulin
levels from GSK-3a KO animals were comparable to those
observed in WT animals.
To assess whether GSK-3a inactivation affects insulin
sensitivity, we carried out insulin tolerance tests in WT
and KO mice. GSK-3a KO animals showed enhanced
ability to clear blood glucose compared to their WT
counterparts (Figure 2C). Enhanced glucose tolerance
and insulin sensitivity were also observed in GSK-3a
KO animals at 16, 24, and 32 weeks of age (data not
shown). GSK-3a KO animals exhibited a significant
reduction in total body fat mass compared to WT ani-
mals (Figure 2D), and total body lean mass was signif-
icantly higher in GSK-3a KO animals compared to WT
animals.
Glucose Transport Is Not Increased in Muscle
or Liver of GSK-3a KO Mice
Immunoblot analysis of total cell membrane preparations
from skeletal muscle revealed no differences in the levelsCell Mof GLUT1 and GLUT4 protein between WT and GSK-3a
KOmice (Figure S2A). Consistent with these observations,
loss of GSK-3a had no effect on basal (2.12 ± 0.37 mmol/
mg/hr WT versus 2.24 ± 0.20 mmol/mg/hr KO) or insulin-
stimulated glucose transport (5.77 ± 0.30 mmol/mg/hr
WT versus 5.30 ± 0.44 mmol/mg/hr KO) in isolated soleus
(Figure S2C) and extensor digitorum longus muscle (data
not shown). Analysis of the glucose-dependent liver
glucose transporter GLUT2 showed comparable GLUT2
protein levels in liver membranes from GSK-3a KO and
WT animals (Figure S2B).
Effects of Insulin and Glucose on Insulin
Signaling Molecules
As GSK-3 is a key component of the insulin signal trans-
duction pathway, we assessed the impact of GSK-3a
deletion on several molecules in this cascade. Phosphor-
ylation of PKB at Thr308 and Ser473 is associated with its
full activation, whereas phosphorylation of GSK-3 (Ser21
of GSK-3a and Ser9 of GSK-3b) results in inactivation of
GSK-3. Insulin-stimulatedPKBphosphorylationwasmark-
edly higher in liver extracts of GSK-3a KOmice comparedetabolism 6, 329–337, October 2007 ª2007 Elsevier Inc. 331
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Tissue-Specific Roles of GSK-3aFigure 3. Effect of GSK-3a Loss on the Insulin Signaling Pathway
(A and B) Liver (A) and muscle (B) from 8-week-old GSK-3a KO (/) andWT (+/+) littermates was extracted at the indicated times after i.p. insulin or
glucose injection, and 20 mg of the protein lysate was resolved by SDS-PAGE. Proteins were detected by immunoblotting with antibodies against
phospho-PKB, PKB, phospho-GSK-3b, GSK-3b, phospho-GS, GS (lower left in [A] and [B]), and IRS-1 (lower right in [A]). b-actin or GAPDH was
used as a loading control. Blots are representative of three separate experiments.
(C) Quantification of immunoreactivity of insulin-stimulated phospho-PKB and phospho-GSK-3b and glucose-stimulated phospho-GS (15 min and
2 hr) fromWT and GSK-3a KO liver tissue. Data are presented as a bar graph showing signal intensity as percentage of WT signal. nR 3 independent
experiments.
(D) Primary hepatocytes were isolated as described in Experimental Procedures and pretreated with or without 25mM glucose for 30min. GS activity
was determined by assaying incorporation of glucose from UDP-[6-3H]D-glucose into glycogen and is expressed as a ratio of activity in the absence
of G6P to activity in the presence of G6P. Lower panel shows a representative phospho-GS immunoblot of assayed lysates. b-actin was used as
a loading control. n = 3 experiments carried out in duplicate; *p < 0.01 versus the respective fasted control.to WT mice (Figure 3A). Consistent with this finding, insu-
lin-stimulated phosphorylation of GSK-3b was higher in
extracts from livers of GSK-3a KO mice than in WT liver
extracts. However, in contrast to in the liver, levels of insu-
lin-stimulated phosphorylation of PKB and GSK-3b were
similar in skeletal muscle from both WT and GSK-3a KO
mice (Figure 3B).
Liver GS is controlled by the allosteric activator
glucose-6-phosphate (G6P) in addition to phosphoryla-
tion. Using a phosphospecific antibody to the GSK-3
site Ser641, GS was found to be less phosphorylated,
and hence more active, in liver extracts from GSK-3a
KO compared to WT control animals (Figure 3A). Acute
(15 min) administration of glucose led to dephosphoryla-
tion of GS in livers from GSK-3a KO mice, whereas no332 Cell Metabolism 6, 329–337, October 2007 ª2007 Elsevierdephosphorylation of GS was observed in control animals
(Figure 3A). However, following 2 hr glucose administra-
tion, the phosphorylation status of GS was comparable
in liver extracts fromGSK-3aKO andWT animals. Expres-
sion of insulin receptor substrate 1 (IRS-1) was markedly
higher in GSK-3a KO compared to WT liver samples
(Figure 3A, lower right panel). In agreement with the
phosphorylation and glucose transport data, analysis of
skeletal muscle revealed negligible differences in insulin-
stimulated dephosphorylation of GS (Figure 3B). Analysis
of isolated primary hepatocytes demonstrated signifi-
cantly higher GS activity in unstimulated GSK-3a KO
hepatocytes compared to WT cells. Although a 30 min
glucose treatment resulted in elevated GS activity in WT
hepatocytes, glucose-stimulated GSK-3a KO hepaticInc.
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Tissue-Specific Roles of GSK-3aFigure 4. Glycogen Deposition in Liver,
Muscle, and Epididymal Fat of GSK-3a
KO and WT Mice
(A and B) Periodic acid Schiff (PAS) staining of
liver (A) and muscle (B) of 8-week-old GSK-3a
KO animals and WT littermate controls follow-
ing fasting or a 2 hr administration of 2 mg/g
glucose by i.p. injection. Images are represen-
tative of four separate animals.
(C–E) Glycogen content was measured in liver
(C), muscle (D), and epididymal fat (E) from
8-week-old GSK-3a KO (black bars) and WT
(white bars) littermates following fasting or
a 2 hr i.p. injection of 2 mg/g glucose. Tissues
were extracted and acid hydrolyzed, and
glycosyl units were assayed using a glucose
reagent hexokinase method (Amresco) as
described in Experimental Procedures. Glyco-
gen content is expressed as mmol glucose/g
tissue. n = 8 animals; *p < 0.05 versus WT for
fasted; *p < 0.001 versus WT for 2 hr glucose.GS activity remained comparable to that observed under
basal conditions (Figure 3D). Analysis of GS phosphoryla-
tion from isolated primary hepatocytes was consistent
with these findings (Figure 3D). Expression analysis of
gluconeogenic genes demonstrated no significant alter-
ation in phosphoenolpyruvate carboxykinase (PEPCK),
phosphofructokinase (PFK), and G6Pase mRNA expres-
sion between GSK-3aKO andWT livers under fasted con-
ditions or following a 2 hr administration of insulin (Fig-
ure S3). However, glucokinase (GCK) mRNA expression
was increased under fasted conditions in GSK-3a KO
samples compared to WT (Figure S3). This difference
was not observed in the presence of insulin.
Increased Glycogen Deposition in GSK-3a
KO Liver
A major contribution to the pathophysiology of diabetes is
impaired storage and utilization of glucose (Cline et al.,
1994; Shulman et al., 1990a). Periodic acid Schiff (PAS)
staining was used to detect glycogen in sections of paraf-
fin-embedded liver fromGSK-3aKOandWTmice. Fasted
WT liver showed minimal glycogen content (Figure 4A),
whereas liver sections from fasted GSK-3a KO animals
exhibited significantly elevated glycogen (Figure 4A).
Glycogen levels 2 hr after glucose administration were
substantially elevated in GSK-3a KO mouse liver com-
pared to WT. In contrast, no differences were observed
in muscle glycogen content between fasted or glucose-
injected WT and GSK-3a KO animals (Figure 4B). Quanti-
tative enzymatic analysis of glycogen was consistent with
the PAS staining such that fasted and glucose-stimulated
liver glycogen was enhanced in GSK-3a KO animals
(Figure 4C) with no significant difference in muscle
(Figure 4D) or epididymal fat pad (Figure 4E) glycogen.CellBoth WT and GSK-3a KO hepatic glycogen levels were
significantly elevated following feeding; however, no dif-
ference was observed between the two animal groups
(Figure S4).
To determine whether the tissue difference in glycogen
levels related to compartmentalization of GSK-3 isoforms,
we isolated the glycogen pellet from liver and muscle of
WT and KO animals (Figure S5A). Although the ratio of
GSK-3a to GSK-3b associated with the glycogen pellet
was comparable between liver and muscle in WT animals,
the ratio of GSK-3a to GSK-3b was significantly higher
in the supernatant of WT muscle than in WT liver
(Figure S5B). Additionally, PP1 association with the glyco-
gen pellet from liver andmuscle was comparable between
the two animal groups (Figure S5A). To assess whether
hepatic GS regulation was GSK-3a-specific, we com-
pared the phosphorylation of GS in liver from WT and
GSK-3a KO animals and from animals with conditional
deletion of GSK-3b in the liver (S.P. and J.R.W., unpub-
lished data). GS phosphorylation was significantly lower
in liver from GSK-3a KO animals compared to WT con-
trols, whereas phosphorylation of GS in GSK-3b KO liver
samples was comparable to that observed in WT animals
(Figure S5C).
DISCUSSION
Acute and chronic inhibition of GSK-3 by either insulin or
cell-permeable chemical inhibitors can result in activation
of GS activity and glycogen deposition in a variety of cells
and tissues (see, e.g., Coghlan et al., 2000; Eldar-Finkel-
man et al., 1996; MacAulay et al., 2003; Orena et al.,
2000). GSK-3 expression and activity are elevated in
diabetic rodents and humans, with consequentialMetabolism 6, 329–337, October 2007 ª2007 Elsevier Inc. 333
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et al., 1996) and severely impaired glycogen deposition
(Shulman et al., 1990b). The majority of the prior studies
have addressed the importance of GSK-3 for glucose
metabolism via either overexpression of GSK-3 mutants
or application of pharmacological inhibitors that block
both GSK-3 isoforms. Here, we present genetic evidence
supporting an essential role for GSK-3a in glucose
homeostasis and demonstrate unique, tissue-specific
physiological functions of GSK-3a and GSK-3b.
Our finding that global loss of GSK-3a results in im-
proved glucose tolerance and insulin sensitivity in mice
is supported by reports demonstrating the beneficial
effects of acute GSK-3 inhibition in mouse models of dia-
betes and obesity (Cline et al., 2002; Henriksen et al.,
2003; Kaidanovich-Beilin and Eldar-Finkelman, 2006).
The enhanced insulin sensitivity observed in GSK-3a KO
mice may be explained by the reduction in total fat mass
and increase in total lean mass. Circulating leptin levels
are directly proportional to total body fat mass (Friedman
and Halaas, 1998); hence, the alteration in body composi-
tion is consistent with our finding that plasma leptin levels
were significantly reduced in fed GSK-3a KO mice com-
pared to WT littermates.
The most striking physiological phenotype of the GSK-
3a KO mice is significant enhancement of fasted and glu-
cose-stimulated hepatic glycogen deposition. Cline et al.
(2002) demonstrated increased liver glycogen deposition
in Zucker diabetic fatty rats treated with GSK-3 inhibitors,
with little effect on skeletal muscle glycogen levels. Inter-
estingly, overexpression of GSK-3b in muscle results in
reduced muscle glycogen deposition accompanied by
a compensatory increase in liver glycogen levels (Pearce
et al., 2004). Liver glycogen accumulation has also been
observed in the absence of muscle glycogen in mice lack-
ing muscle GS (Pederson et al., 2005). These latter studies
suggest that some level of compensatory tissue crosstalk
exists with respect to the regulation of glycogen deposi-
tion. The fact that there were no differences in GS activity
or glycogen deposition in muscle suggests that GSK-3a
may have a minimal role in the regulation of glycogen
synthesis in this tissue. McManus et al. (2005) used
a knockin approach to express constitutively active
GSK-3a and b (GSK-3a21A/21A/GSK-3b9A/9A). They
reported that although insulin failed to stimulate an
increase in GS activity in GSK-3b9A/9A animals, an
activation of GS was observed in response to insulin in
GSK-3a21A/21A animals. The authors concluded that
GSK-3b, rather than GSK-3a, is the primary muscle GS
kinase.
GSK-3a KO liver extracts exhibited enhanced insulin-
stimulated PKB and GSK-3b phosphorylation, whereas
in muscle, phosphorylation of these proteins was compa-
rable betweenWT and KOanimals. The reason behind this
enhanced insulin signaling in the liver but not themuscle is
unclear. A possible explanation for the enhanced liver PKB
and GSK-3b phosphorylation is that IRS-1 serine phos-
phorylation is decreased in GSK-3a KO liver. GSK-3 has
previously been shown to catalyze serine phosphorylation334 Cell Metabolism 6, 329–337, October 2007 ª2007 Elsevierof IRS-1, interfering with receptor-mediated tyrosine
phosphorylation by the insulin receptor, effectively atten-
uating insulin receptor signaling through negative feed-
back (Liberman and Eldar-Finkelman, 2005). Loss of
GSK-3a in the liver may result in reduced IRS-1 serine
phosphorylation and hence augment insulin signaling. He-
patic IRS-1 protein levels were increased markedly in
extracts from GSK-3a KO animals. Previous reports
have shown that acute insulin exposure results in stabili-
zation of IRS-1 (Ruiz-Alcaraz et al., 2005). It has also
been reported that serine/threonine phosphorylation of
IRS-1 promotes its degradation (White, 2002). This mech-
anism is further supported by the finding that in ob/ob
mice, in which GSK-3 activity has been reported to be
elevated (Eldar-Finkelman et al., 1999), IRS-1 expression
is reduced (Kerouz et al., 1997). Furthermore, it has
recently been reported that knockdown of GSK-3a in
muscle cells from diabetic patients results in increased
IRS-1 expression (Ciaraldi et al., 2007).
Our finding that GSK-3a KO mice are viable contrasts
with the embryonic lethality of GSK-3b KO mice (Hoeflich
et al., 2000) and indicates functional divergence between
the isoforms. The importance of GSK-3a has been over-
looked in many areas of research to date due to themajor-
ity of studies focusing on GSK-3b. However, the current
findings demonstrate that GSK-3a is a key regulator of
hepatic glucose metabolism and indicate that GSK-3a
and GSK-3b exhibit divergent physiological roles in mus-
cle and liver tissue. A major concern in utilizing GSK-3
as a drug target is its role in the Wnt signaling pathway,
where inhibition might lead to stabilization of the proto-
oncogene b-catenin. However, GSK-3a KO mice showed
no increased propensity for tumorigenesis (data not
shown). Furthermore, recent studies have demonstrated
that complete loss of GSK-3 (i.e., GSK-3a/b/) in
embryonic stem (ES) cells is required before b-catenin
levels are significantly dysregulated (Doble et al., 2007).
Together, these findings should mitigate previous con-
cerns that inhibition of GSK-3 could be oncogenic and
provide new incentive for examination of GSK-3 as a ther-
apeutic target for type II diabetes, recognizing there are
significant species differences between rodents and
humans in tissue glycogen storage (Carey et al., 2003).
EXPERIMENTAL PROCEDURES
Conditional Knockout Mouse Generation
A targeting vector was employed that upon proper homologous re-
combination replaced exon 2 of the GSK-3a gene with a conditional
variant (LoxP-flanked). The ‘‘arms’’ of homology were obtained by
PCR amplification of genomic DNA flanking exon 2 of the GSK-3a
gene with the proofreading polymerase Platinum Pfx (Invitrogen).
The template DNA for PCR was obtained from a lambda phage clone
isolated by Southern blotting from a library containing genomic DNA
from the mouse strain 129/Ola. PCR products were sequence vali-
dated. The targeting vector (50 mg) was linearized with NdeI, purified,
and electroporated into 8 3 106 cells of the hybrid 129/B6 ES cell
line designated G4 (George et al., 2007) with a Bio-Rad Gene Pulser II
(250V, 500 mF). After selection in G418-containingmedium (250 mg/ml),
resistant clones were screened by PCR and Southern blotting
(Figure 1B). One of the validated ES cell clones (+3.20*) was used inInc.
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from the ES cells, as has been previously reported for other hybrid ES
cell lines (Li et al., 2005). The genotype of the eight resulting mice was
confirmed by PCR analysis.
Male GSK-3a KO mice and WT littermate controls were housed five
per cage with a light/dark cycle of 12 hr in the Princess Margaret Hos-
pital animal facility, with free access to food and water except where
noted. For assessment of fat and lean mass, a mouse whole-body
magnetic resonance analyzer (Echo Medical Systems) was used.
Glucose and Insulin Tolerance Tests
Glucose tolerance tests were carried out following overnight fast (16–
18 hr). Mice were administered 2 mg/g glucose by i.p. injection, and
blood glucose was assayed from the tail vein using a OneTouch Ultra-
Smart Blood Glucose Monitoring System (LifeScan) at the indicated
times. For insulin tolerance testing, animals were fasted for 5 hr prior
to an i.p. injection of 1 mU/g insulin.
Plasma Insulin, Adiponectin, Leptin, and Triglyceride Assays
Blood was collected from the tail vein of random-fed mice following an
overnight fast alone or after i.p. glucose administration as stated in the
figure legends. Plasmawas assayed for insulin, adiponectin, and leptin
using a rat/mouse insulin ELISA kit, adiponectin ELISA kit, and mouse
leptin ELISA kit, respectively (Linco Research). Plasma triglycerides
were determined using aWako L-Type Triglyceride-H kit (Wako Chem-
icals USA, Inc.).
Preparation of Tissue Lysates and Cytosolic
b-Catenin Isolation
Mice were fasted overnight and treated with 150 mU/g insulin for
10 min or 2 mg/g glucose for either 15 or 120 min by i.p. injection. Tis-
sues were extracted in lysis buffer (150 mM NaCl, 1% NP-40, 0.5%
DOC, 0.1% SDS, 1 mM EDTA, 50 mM Tris [pH 8.0], 10 mM sodium
fluoride, 1 mM sodium orthovanadate, 10 mM b-glycerophosphate,
and one protease inhibitor cocktail tablet/50 ml). Lysates were centri-
fuged at 16,0003 g, 4C for 15min, and protein concentration was de-
termined by Lowry assay (Lowry et al., 1951).
For cytoplasmic b-catenin isolation, tissue extracts from fastedmice
were lysed in hypotonic lysis buffer (50 mM Tris [pH 7.4], 1 mM EDTA,
25 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM b-glycer-
ophosphate, and protease inhibitors). Lysates were centrifuged at
300,000 3 g, 4C for 30 min, and the supernatant was used as the
source for cytosolic b-catenin.
Immunoblotting
Twenty micrograms of protein was resolved by SDS-PAGE and immu-
noblotted with antibodies against GSK-3a/b (1:10,000, BioSource),
phospho-GSK-3b (1:1,000, Cell Signaling), b-catenin (1:1,000, BD
Transduction Laboratories), PKB (1:1,000, Cell Signaling), phospho-
PKB Ser473 (1:1,000, Cell Signaling), GS (GYS1, 1:1,000, Chemicon),
GS (GYS2, 1:1,000, gift from J. Guinovart, University of Barcelona),
phospho-GS (1:1,000, Cell Signaling), IRS-1 (1 mg/ml, Upstate), PP1
(1:1,000, BD Transduction Laboratories), b-actin (1:20,000, Abcam),
GAPDH (1:100,000, Abcam), GLUT1 (1:1,000, Chemicon), GLUT4
(1:1,000, Chemicon), GLUT2 (1:1,000, Chemicon), and caveolin-1
(1:500, Abcam) overnight at 4C. Washed membranes were incubated
with species-appropriate HRP-linked secondary antibodies (1:10,000),
and visualizationwas performed using ECL reagent exposure to Kodak
film. Densitometry was performed using an Alpha Innotech FluorChem
HD2.
Primary Hepatocyte Isolation and Culture
Eight-week-old GSK-3a KO and WT littermate control animals were
anesthetized with isoflurane/oxygen. Hepatocytes were then isolated
by retrograde, nonrecirculating in situ collagenase liver perfusion. In
brief: livers were perfused with liver perfusion medium (pH 7.4, Invitro-
gen) followed by liver digest medium (pH 7.4, Invitrogen). The digested
liver was removed and washed in chilled hepatocyte wash mediumCell M(Invitrogen). Viable cells were harvested by Percoll (Sigma) gradient.
The final pellet was resuspended in Williams’ E medium containing
200 nM L-glutamine, 5% FBS, 1 mg/ml insulin, 100 units/ml penicillin,
and 100 mg/ml streptomycin. Cell viability was greater than 90%.
Hepatocytes were plated at 300,000 cells per well of six-well plates.
Hepatocytes were allowed to recover and attach for 4 hr before
replacement of the medium with serum-free aMEM overnight. Prior
to lysis (50 mM Tris [pH 7.4], 0.27 M sucrose, 1 mM sodium orthovana-
date [pH 10], 1 mMEDTA, 1mMEGTA, 10mM sodium b-glycerophos-
phate, 50mM sodium fluoride, 5mM sodium pyrophosphate, 1% (w/v)
Triton X-100, 0.1% (v/v) 2-mercaptoethanol, and protease inhibitor
cocktail), glucose (25 mM) was added for 30 min, and cells were
washed three times in ice-cold saline (150 mM), scraped, and homog-
enized with a syringe needle prior to centrifugation.
Glycogen Synthase Activity Assay
GS activity was assayed as described previously (MacAulay et al.,
2005). Assay buffer (67 mM Tris [pH 7.5], 5 mM DTT, 89 mM UDP-
glucose, 6.7 mM EDTA, 13 mg/ml glycogen, and 1 mCi/assay UDP-
[6-3H]D-glucose) was added to 45 ml of lysate in the presence or
absence of 20 mM G6P. After incubation at 37C for 30 min, the reac-
tion was stopped by spotting onto 31ETCHR Whatman filter paper
(Whatman International Ltd.) and washed three times in 66% ethanol
for 20 min. Finally, filters were washed in acetone and air dried before
incorporation of glucose from UDP-[6-3H]D-glucose (GE Healthcare)
into glycogen was counted by liquid scintillation. GS activity was
expressed as a ratio of activity in the absence of G6P to activity in
the presence of G6P.
Periodic Acid Schiff Staining
Liver and muscle frommice either fasted overnight or fasted overnight
and then given an i.p. injection of 2 mg/g glucose for 2 hr were ex-
tracted and fixed in 10% neutral buffered formalin overnight at 4C.
Tissues were sectioned and subjected to PAS staining prior to imaging
(Amalfitano et al., 1999).
Glycogen Determination
Fifty milligrams of gastrocnemius, 20 mg of liver, or 50 mg of epididy-
mal fat from mice fed as normal, fasted overnight, or fasted overnight
and then given a 2 hr i.p. injection of 2 mg/g glucose was acid hydro-
lyzed in 2 M HCl at 95C for 2 hr. Following neutralization in 2 M NaOH,
glycosyl units were assayed using a glucose reagent hexokinase
method (Amresco) as described previously (Bondar and Mead, 1974).
Statistical Analysis
For multiple comparisons, analysis was performed using either two-
way analysis of variance (ANOVA) followed by a Bonferroni post hoc
test or unpaired Student’s t test. Data analysis was performed using
GraphPad Prism software, and differences were considered statisti-
cally significant at p < 0.05 unless otherwise stated.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and five figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/
6/4/329/DC1/.
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